about
A restricted population of CB1 cannabinoid receptors with neuroprotective activityNeuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndromeCannabinoids and neuroprotection in basal ganglia disorders.Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.The endocannabinoid system in Huntington's disease.The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.New serotonin 5-HT(1A) receptor agonists with neuroprotective effect against ischemic cell damage.Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study.Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders
P50
Q33730578-B47046DA-81E3-4D61-A8E8-D7173EF7B901Q34440282-FB19E3A2-0389-47E7-80BB-6FAC9A94AC5EQ36056302-E1160E11-BFA4-4262-91BE-E1B1C91A8030Q36719661-8FE7324C-3979-46F0-82F1-F96AD31004E1Q36977766-942325B1-9E42-41F0-A1E6-20B2DD54B8F2Q37253331-9E4D1B40-1EF4-4F19-936B-2A0375D6C5A9Q37264872-5245A8A8-45D7-435C-9175-2A9748E5A7BCQ37577451-5B1B19B0-692E-4BC4-8F46-3E0A2B173E21Q42289980-F9D42235-5955-4E5D-9B41-1478DE8BF532Q42478056-45EE66E4-8FC7-4C31-B0CB-DAC1ADC854A2Q42725691-0DB3859A-17AB-45EF-9050-BC566A010970Q43266820-A2CDF7EC-7A36-40D9-9AC9-4995F87BA576Q43267409-3C3E6839-D9AE-4A6C-BC55-72E996DE8349Q45303268-AF45345A-6994-4065-9FE9-04D1DC447DEEQ46123071-620B5692-732C-4449-9EAB-E71FECBE9CE7Q91004219-EF06B41C-1D63-41BC-BB51-8A172B24224E
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Onintza Sagredo
@en
Onintza Sagredo
@nl
type
label
Onintza Sagredo
@en
Onintza Sagredo
@nl
prefLabel
Onintza Sagredo
@en
Onintza Sagredo
@nl
P31
P496
0000-0003-0452-3223